NasdaqGS - Delayed Quote USD

Gilead Sciences, Inc. (GILD)

67.08 +0.05 (+0.07%)
At close: April 24 at 4:00 PM EDT
67.26 +0.18 (+0.27%)
After hours: April 24 at 7:29 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Daniel P. O'Day Chairman & CEO 6.99M -- 1964
Mr. Andrew D. Dickinson Chief Financial Officer 2.66M -- 1970
Ms. Deborah H. Telman Executive VP of Corporate Affairs, General Counsel & Corporate Secretary 2.56M -- 1965
Ms. Johanna Mercier Chief Commercial Officer 3.1M -- 1970
Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer 2.79M -- 1964
Ms. Sandra Patterson Senior VP, Corporate Controller & Principal Accounting Officer -- -- 1967
Ms. Jacquie Ross C.F.A. Vice President of Investor Relations -- -- --
Ms. Jyoti K. Mehra Executive Vice President of Human Resources -- -- 1976
Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio -- -- 1962
Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe -- -- 1946

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000 https://www.gilead.com
Sector: 
Healthcare
Full Time Employees: 
18,000

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate Governance

Gilead Sciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 1. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 1; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 25, 2024
Gilead Sciences, Inc. Earnings Call

Related Tickers

BMY Bristol-Myers Squibb Company
48.86
-0.27%
 
BIIB Biogen Inc.
201.99
+4.56%
 
AMGN Amgen Inc.
273.01
-0.19%
 
PFE Pfizer Inc.
26.27
-0.19%
 
ABBV AbbVie Inc.
167.80
-1.03%
 
JNJ Johnson & Johnson
148.53
-0.69%
 
MRK Merck & Co., Inc.
127.00
+0.09%
 
GSK GSK plc
40.86
-0.92%
 
AZN AstraZeneca PLC
71.20
+0.49%
 
NVS Novartis AG
98.35
+1.10%